Altona North

Researchers are evaluating the safety and effectiveness of a topical gel called zabalafin for treating people with mild to moderate atopic dermatitis, also known as eczema. This Phase 2b study includes two groups: one with mild to moderate atopic dermatitis and another group with mild to moderate atopic dermatitis plus a secondary skin infection. The goal is to compare zabalafin hydrogel against a placebo (vehicle) over a 16-week treatment period. Participants will be randomly assigned to receive either zabalafin hydrogel or a placebo in a 2:1 ratio. The study includes up to 72 participants across 10 sites in Australia. After up to 2 weeks of screening, participants will apply the assigned gel and visit the study site every 2 weeks for the first month, then monthly until the 16-week treatment ends. This double-blind study means neither participants nor researchers know who receives which treatment. During the study, participants will undergo regular evaluations including a clinical assessment using the validated Investigator's Global Assessment scale (vIGA) to measure treatment effects. Researchers will monitor the severity of eczema, skin lesion size, itching intensity, and any side effects. Participants must follow study procedures, including avoiding other topical products on affected skin areas and attending scheduled visits for up to 113 days.

Researchers are conducting a Phase 2, randomized, double-blind, international multicenter study to assess the safety and effectiveness of ABP-745 in adults experiencing acute gout flares. The study compares ABP-745 with standard colchicine treatment and placebo to evaluate their impact on reducing pain and swelling. The main focus is to measure pain relief after treatment using a visual analog scale. Participants are assigned to one of four groups receiving either two different doses of ABP-745 with colchicine placebo, colchicine with ABP-745 placebo, or double placebo tablets. Treatments are given orally. The study monitors pain changes 24 hours after the first dose. The trial includes adults aged 18 to 70 with a history of gout flares and evaluates responses shortly after flare onset. During the study, participants will undergo assessments including pain scoring to track changes in joint pain. Researchers will monitor safety and treatment effects throughout the treatment period. The total participation timeline includes screening and treatment phases, with attention to medication stability and lifestyle consistency. Pain score changes 24 hours post-treatment serve as the primary outcome measure for evaluating treatment efficacy.

Researchers are evaluating the effects of Efsubaglutide Alfa, an investigational drug, in adults who are overweight or obese. This phase II trial aims to assess its safety, effectiveness, how the body processes the drug, and immune responses. Participants include those with a body mass index (BMI) between 27 and 30 kg/m2 with at least one related health condition, or those with a BMI of 30 kg/m2 or higher regardless of other conditions. The study is designed as a multicenter, double-blind, randomized, placebo-controlled trial to provide reliable results. Participants will receive different doses and schedules of Efsubaglutide Alfa or a placebo during a 22-week treatment period. The doses include 20 mg weekly, 40 mg weekly or every two weeks, and 80 mg weekly or every four weeks. The study starts with a 2-week screening period to determine eligibility, followed by the 22-week double-blind treatment phase where neither participants nor researchers know who receives the drug or placebo. After treatment, there is a 4-week follow-up period without medication to monitor participants. Throughout the study, participants will have regular visits and assessments to monitor changes in body weight from the start of treatment. Researchers will also evaluate safety and drug effects through physical exams, laboratory tests, and tracking of any side effects. The total study time for participants is approximately 28 weeks, including screening, treatment, and follow-up. The main goal is to measure the percentage change in body weight after 22 weeks of treatment with Efsubaglutide Alfa.